MARKET

RXRX

RXRX

Recursion Pharmaceuticals, Inc.
NASDAQ
9.64
+0.27
+2.88%
After Hours: 9.88 +0.24 +2.49% 16:39 02/03 EST
OPEN
9.10
PREV CLOSE
9.37
HIGH
9.74
LOW
9.08
VOLUME
1.31M
TURNOVER
0
52 WEEK HIGH
14.18
52 WEEK LOW
4.920
MARKET CAP
1.83B
P/E (TTM)
-6.6968
1D
5D
1M
3M
1Y
5Y
Insider Sell: Recursion Pharmaceuticals
Insider Sell: Recursion Pharmaceuticals
MT Newswires · 9h ago
Berenberg Bank Keeps Their Buy Rating on Recursion Pharmaceuticals (RXRX)
TipRanks · 1d ago
--Berenberg Bank Adjusts Recursion Pharmaceuticals Price Target to $33 From $42, Maintains Buy Rating
--Berenberg Bank Adjusts Recursion Pharmaceuticals Price Target to $33 From $42, Maintains Buy Rating
MT Newswires · 1d ago
Tracking Baillie Gifford's 13F Portfolio - Q4 2022 Update
Seeking Alpha · 4d ago
SVB Securities Reaffirms Their Hold Rating on Recursion Pharmaceuticals (RXRX)
TipRanks · 01/27 04:25
Recursion Releases MolRec, A Compound Intelligence Tool For Drug Discovery, Alongside The Largest Of Its Kind Open-Source Dataset During First R&D Day
Benzinga · 01/26 13:35
Recursion Pharmaceuticals Releases Compound Intelligence Tool for Drug Discovery, Cellular Imaging Dataset
Recursion Pharmaceuticals Releases Compound Intelligence Tool for Drug Discovery, Cellular Imaging Dataset
MT Newswires · 01/26 11:53
Recursion Pharmaceuticals (RXRX) presents at 41st Annual J.P. Morgan Healthcare Conference - Slideshow
Seeking Alpha · 01/11 18:46
More
About RXRX
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company decoding biology by integrating technology across biology, chemistry, automation, machine learning, and engineering to industrialize drug discovery. The Company’s platform includes the Recursion Operating System, which combines an advanced infrastructure layer to generate proprietary biological and chemical datasets, and the Recursion Map, a suite of custom software, algorithms, and machine learning tools. The Company’s programs include REC-994, REC-2282, REC-4881, and REC-3599. REC-994 is an orally bioavailable, superoxide, scavenger small molecule being developed for the treatment of CCM. REC-2282 is developed for the treatment of neurofibromatosis type 2. REC-4881 is developed for the treatment of familial adenomatous polyposis. REC-3599 is developed for the treatment of GM2 gangliosidosis.

Webull offers kinds of Recursion Pharmaceuticals Inc stock information, including NASDAQ:RXRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RXRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RXRX stock methods without spending real money on the virtual paper trading platform.